What is Renovaro's earnings per share (EPS)?

Renovaro (RENB) reported diluted earnings per share of -$1.08 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Renovaro Financials

RENB

Trailing 12 months to March 31, 2026

Revenue Not reported for the trailing 12 months

Net Income Not reported for the trailing 12 months

EPS (Diluted) -$1.08 FY2025 annual

Free Cash Flow Not reported for the trailing 12 months

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Mar 31, 2026 Reported May 15, 2026 Currency USD FYE June

This page shows Renovaro (RENB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RENB FY2025 2026-08-15

Shrinking liquidity and external financing dependence are now the dominant mechanics visible in Lunai Bioworks' reported finances.

In the most recent year, current ratio was just 0.04x and cash had shrunk to $93K, so short-term obligations were no longer buffered by liquid resources. Operations then used $7.9M of cash while financing supplied $8.4M, a pattern that shows the company functioning on outside funding rather than cash generated by its own operating base.

The expense mix has also changed sharply: R&D fell to $537K while SG&A remained $17.9M. That suggests the reported cost structure is now driven less by active development work and more by overhead, transaction friction, or public-company upkeep, which changes what each new financing round is effectively paying for day to day.

The balance sheet has compressed fast, with total assets falling from $189.6M to $8.2M across the reported period. Because goodwill still represented 72.4% of those assets and equity was -$21.3M, the remaining asset base offers limited flexibility for creditors or new capital providers if operating cash needs continue.

Financial Health Signals

Financial health score not available

Renovaro does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

EPS (Diluted)

-$1.08

Renovaro earned -$1.08 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

EBITDA

Not reported for fiscal year 2025.

Net Income

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt

$93K

YoY-58.0%

5Y CAGR-59.7%

10Y CAGR-29.4%

Renovaro held $93K in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

18M

Renovaro had 18M shares outstanding in fiscal year 2025.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

None of these metrics is reported for fiscal year 2025.

Capital Allocation

R&D Spending

$537K

YoY-80.2%

5Y CAGR-35.2%

Renovaro invested $537K in research and development in fiscal year 2025. This represents a decrease of 80.2% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

RENB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RENB quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY14	FY13	FY12	FY12
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$43K	$0-100.0%	$33K-47.8%	$63K	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$5K	$296K+170.5%	$109K+69.8%	$64K	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$37K	-$296K-286.3%	-$77K-4746.8%	-$2K	N/A
R&D Expenses	N/A	$537K-80.2%	$2.7M-35.0%	$4.2M-50.3%	$8.4M-46.7%	$15.7M+234.9%	$4.7M+87.9%	$2.5M+304.9%	$617K+883.0%	$63K-92.2%	$804K	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$17.9M-27.2%	$24.6M+60.3%	$15.3M+6.9%	$14.3M+89.6%	$7.6M+6.1%	$7.1M-15.4%	$8.4M+115.9%	$3.9M+317.6%	$934K-24.1%	$1.2M	$1.6M+33.3%	$1.2M+19.1%	$1.0M	$34K
Operating Income	N/A	N/A	-$81.6M-111.7%	-$38.6M+66.8%	-$116.1M-396.0%	-$23.4M-96.3%	-$11.9M-8.5%	-$11.0M-106.2%	-$5.3M-122.0%	-$2.4M-13.2%	-$2.1M	-$2.4M-39.7%	-$1.7M	N/A	-$34K
Interest Expense	N/A	$726K-28.2%	$1.0M+74.3%	$580K+55.7%	$373K-1.8%	$380K+264.0%	$104K+242411.6%	$43-100.0%	$143K	N/A	$2K	$85K-87.0%	$653K-7.4%	$705K	N/A
Income Tax	N/A	$1K	$0	N/A	$34+100.0%	-$125K	N/A	N/A	-$112K-72.2%	-$65K+86.0%	-$463K	-$178K	N/A	N/A	$0
Net Income	N/A	N/A	-$88.4M-122.8%	-$39.7M+65.0%	-$113.4M-324.5%	-$26.7M-134.1%	-$11.4M+36.6%	-$18.0M-185.4%	-$6.3M-194.6%	-$2.1M-23.5%	-$1.7M	-$2.4M-10.4%	-$2.1M	N/A	-$34K
EPS (Diluted)	—	-$1.08	-$0.91	-$0.71+67.1%	-$2.16	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$21K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$21K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$16K-65.2%	$46K+87.9%	$24K	N/A	N/A	$161K-58.7%	$390K	N/A
SG&A Expenses	$1.4M-19.5%	$1.8M-26.7%	$2.4M	N/A	$4.2M-3.0%	$4.4M-17.9%	$5.3M	N/A
Operating Income	-$1.5M+19.0%	-$1.8M+44.9%	-$3.3M	N/A	-$4.2M+8.4%	-$4.5M+91.5%	-$53.3M	N/A
Interest Expense	$108K-11.1%	$122K-0.7%	$122K	N/A	$189K+90.8%	$99K-60.5%	$250K	N/A
Net Income	-$2.6M-42.9%	-$1.8M-163.8%	$2.8M	N/A	$189K+102.6%	-$7.3M+83.6%	-$44.2M	N/A
EPS (Diluted)	-$0.10-25.0%	-$0.08	$0.13	N/A	$0.00+100.0%	-$0.45+83.7%	-$2.76	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Income Tax.

RENB Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RENB quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY14	FY13	FY12	FY12
Total Assets	$8.2M-95.0%	$163.1M+179.8%	$58.3M-31.1%	$84.6M-55.4%	$189.6M+6.5%	$178.1M-1.0%	$179.9M-1.4%	$182.5M+3935.7%	$4.5M+419.3%	$871K	$5.2M+1063.2%	$450K+24.1%	$363K	$14K
Current Assets	$1.0M-47.6%	$2.0M-22.1%	$2.6M-73.2%	$9.6M-54.2%	$20.9M+133.7%	$8.9M-28.4%	$12.5M-20.7%	$15.8M+275.4%	$4.2M+473.2%	$732K	$5.0M+3466.5%	$141K+33.6%	$106K	$14K
Cash & Equivalents	$93K-58.0%	$220K-88.2%	$1.9M-79.6%	$9.2M-55.6%	$20.7M+137.6%	$8.7M-29.2%	$12.3M-21.3%	$15.6M+295.8%	$3.9M+16768.0%	$23K	$3.0M+15909.5%	$19K+329.0%	$4K	$336
Goodwill	$6.0M-96.3%	$159.3M+1268.8%	$11.6M0.0%	$11.6M0.0%	$11.6M0.0%	$11.6M0.0%	$11.6M0.0%	$11.6M	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$29.6M-5.0%	$31.2M+164.0%	$11.8M-1.8%	$12.0M-19.6%	$14.9M+26.3%	$11.8M+74.5%	$6.8M-71.5%	$23.8M+695.0%	$3.0M+98.2%	$1.5M	$1.8M-17.7%	$2.1M-54.9%	$4.7M	$27K
Current Liabilities	$29.2M-3.8%	$30.3M+175.0%	$11.0M+70.9%	$6.5M+242.1%	$1.9M+41.3%	$1.3M+20.2%	$1.1M+27.1%	$874K-70.8%	$3.0M+98.2%	$1.5M	$1.8M-17.7%	$2.1M+2.3%	$2.1M	$27K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$103K	$100K-86.3%	$728K	N/A	N/A
Total Equity	-$21.3M-116.2%	$132.0M+183.8%	$46.5M-36.0%	$72.6M-58.4%	$174.7M+5.0%	$166.3M-3.9%	$173.1M+9.0%	$158.7M+10256.5%	$1.5M+340.5%	-$637K	$3.5M+306.8%	-$1.7M+61.4%	-$4.4M	-$14K
Retained Earnings	-$510.5M-53.5%	-$332.5M-36.2%	-$244.0M-19.4%	-$204.3M-124.8%	-$90.9M-41.6%	-$64.2M-21.6%	-$52.8M-51.8%	-$34.8M-22.2%	-$28.4M-8.1%	-$26.3M	-$21.9M-12.1%	-$19.5M-12.4%	-$17.4M	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$9.9M+47.9%	$6.7M-4.2%	$7.0M-15.4%	$8.2M-93.0%	$117.7M+5.7%	$111.3M-8.6%	$121.8M-25.3%	$163.1M
Current Assets	$3.7M+625.5%	$514K-35.7%	$800K-23.5%	$1.0M-71.5%	$3.7M+114.7%	$1.7M-12.3%	$1.9M-2.5%	$2.0M
Cash & Equivalents	$3.2M+541.8%	$492K-21.3%	$625K+574.0%	$93K-90.0%	$923K+196.1%	$312K+41.3%	$221K0.0%	$220K
Accounts Receivable	N/A	N/A	N/A	N/A	$964K	N/A	N/A	N/A
Goodwill	$6.0M0.0%	$6.0M0.0%	$6.0M0.0%	$6.0M-94.7%	$112.6M+4.3%	$108.0M-8.6%	$118.2M-25.8%	$159.3M
Total Liabilities	$19.4M-4.0%	$20.2M+1.1%	$20.0M-32.4%	$29.6M+0.8%	$29.3M+0.2%	$29.3M+23.3%	$23.7M-23.8%	$31.2M
Current Liabilities	$19.3M-3.6%	$20.0M+1.4%	$19.7M-32.4%	$29.2M+1.1%	$28.8M+0.8%	$28.6M+24.2%	$23.0M-24.0%	$30.3M
Total Equity	-$9.6M+29.5%	-$13.5M-3.9%	-$13.0M+38.9%	-$21.3M-124.2%	$88.4M+7.7%	$82.1M-16.3%	$98.1M-25.7%	$132.0M
Retained Earnings	-$512.0M-0.5%	-$509.4M-0.4%	-$507.6M+0.6%	-$510.5M-33.0%	-$383.7M0.0%	-$383.9M-1.9%	-$376.7M-13.3%	-$332.5M

Not reported in any period shown, so not listed: Inventory, Long-Term Debt.

RENB Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RENB quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY14	FY13	FY12	FY12
Operating Cash Flow	-$5.3M	-$7.9M+28.2%	-$11.0M+6.8%	-$11.8M+25.2%	-$15.7M+23.7%	-$20.6M-97.1%	-$10.5M-22.9%	-$8.5M-96.1%	-$4.3M-268.4%	-$1.2M+20.0%	-$1.5M	-$2.0M+4.5%	-$2.1M-128.4%	-$933K	-$20K
Capital Expenditures	N/A	N/A	$70K+136.5%	$30K+477.5%	$5K-89.5%	$49K-73.5%	$184K-74.3%	$717K+2288.9%	$30K	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	-$11.0M+6.5%	-$11.8M+25.0%	-$15.7M+23.8%	-$20.7M-94.1%	-$10.6M-15.4%	-$9.2M-111.2%	-$4.4M	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$1.5M	-$500K+60.3%	-$1.3M-4132.5%	-$30K-477.5%	-$5K+89.5%	-$49K+73.5%	-$184K+74.3%	-$717K-24.5%	-$576K-193.5%	-$196K-118.6%	$1.1M	-$2.0M-1758.8%	-$105K-24.1%	-$85K	-$13K
Financing Cash Flow	$6.2M	$8.4M-20.3%	$10.5M+132.9%	$4.5M+6.2%	$4.3M-87.0%	$32.6M+352.8%	$7.2M+19.6%	$6.0M-64.0%	$16.7M+203.5%	$5.5M	N/A	$6.7M	N/A	$857K	$34K

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$1.0M+4.1%	-$1.1M+20.6%	-$1.3M+25.5%	-$1.8M-21.8%	-$1.5M+41.9%	-$2.6M-26.9%	-$2.0M+16.5%	-$2.4M
Capital Expenditures	$0	N/A	N/A	N/A	N/A	N/A	N/A	$24K
Free Cash Flow	-$1.0M	N/A	N/A	N/A	N/A	N/A	N/A	-$2.4M
Investing Cash Flow	$0+100.0%	-$1K-100.2%	$545K-43.5%	$964K	N/A	N/A	$0+100.0%	-$53K
Financing Cash Flow	$3.7M+289.8%	$950K-29.3%	$1.3M+653.2%	$178K-95.0%	$3.6M+38.3%	$2.6M+27.7%	$2.0M-17.7%	$2.5M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

RENB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

RENB quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY14	FY13	FY12	FY12
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	87.7%	N/A	-233.6%	-2.5%	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-4959.0%	N/A	-5306.9%	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-4057.2%	N/A	-6553.2%	N/A	N/A
Return on Equity	N/A	-67.0%+18.3pp	-85.3%+70.9pp	-156.2%-140.9pp	-15.3%-8.4pp	-6.9%+3.5pp	-10.4%-6.4pp	-4.0%+135.8pp	-139.8%	N/A	-68.1%	N/A	N/A	N/A
Return on Assets	N/A	-54.2%+13.9pp	-68.1%+66.0pp	-134.0%-119.9pp	-14.1%-7.7pp	-6.4%+3.6pp	-10.0%-6.6pp	-3.5%+43.9pp	-47.4%+151.9pp	-199.3%	-45.3%+431.5pp	-476.7%	N/A	-252.8%
Current Ratio	0.040.0x	0.07-0.2x	0.23-1.3x	1.48-9.6x	11.08+4.4x	6.70-4.6x	11.25-6.8x	18.04+16.6x	1.40+0.9x	0.49	2.87+2.8x	0.070.0x	0.05	0.50
Debt-to-Equity	N/A	0.240.0x	0.25+0.1x	0.17+0.1x	0.090.0x	0.070.0x	0.04-0.1x	0.15-1.8x	1.95	N/A	0.03	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	100.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-7054.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-12278.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	0.2%+9.1pp	-8.8%+36.2pp	-45.1%	N/A
Return on Assets	-26.1%+0.9pp	-27.0%-67.5pp	40.5%	N/A	0.2%+6.7pp	-6.5%+29.8pp	-36.3%	N/A
Current Ratio	0.19+0.2x	0.030.0x	0.040.0x	0.04-0.1x	0.13+0.1x	0.060.0x	0.080.0x	0.07
Debt-to-Equity	N/A	N/A	N/A	N/A	0.330.0x	0.36+0.1x	0.240.0x	0.24
FCF Margin	-4903.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$21.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Radiopharm Theranostics Ltd RADX

$18.3M

Tempest Therapeutics Inc TPST

$17.9M

Acrivon Therapeutics, Inc. ACRV

$89.1M

Barinthus Biotherapeutics plc BRNS

$28.9M

Bioatla, Inc. BCAB

$5.2M

Where Renovaro Ranks

Frequently Asked Questions

What is Renovaro's operating cash flow?

Renovaro (RENB) recorded an outflow of $7.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Renovaro's total assets?

Renovaro (RENB) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Renovaro spend on research and development?

Renovaro (RENB) invested $537K in research and development during fiscal year 2025.

How many shares does Renovaro have outstanding?

Renovaro (RENB) had 18M shares outstanding as of fiscal year 2025.

What is Renovaro's current ratio?

Renovaro (RENB) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Why is Renovaro's debt-to-equity ratio negative or not reported?

Renovaro (RENB) has negative shareholder equity of -$21.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.